<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04278287</url>
  </required_header>
  <id_info>
    <org_study_id>19/325-2109</org_study_id>
    <nct_id>NCT04278287</nct_id>
  </id_info>
  <brief_title>Chemoradiotherapy in Unresectable Esophageal Cancer</brief_title>
  <official_title>A Phase I/II Study of Chemoradiotherapy Using Albumin-Bound Paclitaxel and Cisplatin in Unresectable Esophageal Squamous Cell Carcinomas Based on Nutritional Risk Screening Score (NRS2002)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of
      chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal
      squamous cell carcinomas based on Nutritional Risk Screening NRS2002.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control rate</measure>
    <time_frame>1 year from the start of treatment to tumor recurrence</time_frame>
    <description>Control rate of primary esophageal cancer and metastatic lymph nodes within irradiation fields</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with acute toxicities</measure>
    <time_frame>10 week, from the start of treatment to 1 month after chemoradiotherapy</time_frame>
    <description>Acute toxicities are evaluated by NCI-CTC version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>5.5 week</time_frame>
    <description>Objective Response Rate are evaluated by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>1 year, 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year, 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year, 2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiomics analysis</measure>
    <time_frame>5.5 week</time_frame>
    <description>Radiomics analysis for tumor response and survival prediction with pre- and post-chemoradiotherapy based on MRI and CT simulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ctDNA analysis</measure>
    <time_frame>4 week, 2 month, 1 year, 2 year</time_frame>
    <description>ctDNA analysis to monitor therapeutic efficacy including tumor response and survival outcome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Chemoradiotherapy</condition>
  <condition>Albumin-bound Paxlitaxel</condition>
  <condition>Unresectable Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Albumin-Bound Paclitaxel and Cisplatin based chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemoradiotherapy arm receives intensity-modulated radiation therapy, volume modulated arc therapy or tomotherapy concurrently with albumin-bound paclitaxel and cisplatin (weekly intravenous infusion in 5-6 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>59.92Gy and 2.14Gy in 28 fractions to PGTV and 50.4Gy and 1.8Gy in 28 fractions 5 days every week in 5.5 weeks.</description>
    <arm_group_label>Albumin-Bound Paclitaxel and Cisplatin based chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin-Bound Paclitaxel</intervention_name>
    <description>100mg/d weekly,repeatedly on the first day,by intravenous infusion in 5-6 weeks.</description>
    <arm_group_label>Albumin-Bound Paclitaxel and Cisplatin based chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>25mg/m2 weekly,by intravenous infusion in 5-6 weeks.</description>
    <arm_group_label>Albumin-Bound Paclitaxel and Cisplatin based chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18~75 years

          -  Pathologically or cytologically proven unresectable esophageal squamous cell
             carcinomas in patients staged as T3N1M0-1b and T4N0-1M0-1b(AJCC 6th TNM staging,M1b
             limited to clavicular or celiac lymph node metastasis)

          -  Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences

          -  ECOG PS score: 0~1

          -  NRS2002 score &lt;3

          -  Estimated survival time â‰¥3 months

          -  Normal organ and marrow function as defined below:

        Hemoglobin: greater than or equal to 100g/L ;Leukocytes: greater than or equal to 4,000
        G/L; Neutrophil: greater than or equal to 2,000 G/L; Platelets: greater than or equal to
        100,000/mm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater
        than or equal to 60 ml/min; AST/ALT: less than or equal to 2.5 times the upper limit; Total
        bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5
        times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than
        or equal to 1.5 times the upper limit

          -  Informed consent

        Exclusion Criteria:

          -  With any distant metastasis out of regional lymphatic drainage or in liver, lung,
             bone, CNS, etc

          -  Patients with other cancer history in 5 years except cervical carcinoma in situ and
             non-malignant melanoma skin cancer

          -  Existing active infection such as active tuberculosis and hepatitis

          -  History of myocardial infarction within the past 6 months or history of ventricular
             arrhythmia

          -  Uncontrolled illness including, but not limited to, active infection, symptomatic
             heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness

          -  History of allergic reactions attributed to paclitaxel, albumin or cisplatin

          -  Participation in other clinical trials currently or within 4 weeks of selection

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xin Wang, MD</last_name>
    <phone>+861013311583220</phone>
    <email>beryl_wx2000@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, MD</last_name>
      <phone>+861013311583220</phone>
      <email>beryl_wx2000@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>July 18, 2020</last_update_submitted>
  <last_update_submitted_qc>July 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Wang Xin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

